The purpose of the project is to fund the molecular characterization of models for distribution that probably would not have as complete annotation (e.g. the parent tumor and sometime normal could be missing), would increase the number of models that would have whole genome sequencing at 15X, whole exome sequencing at 150X, transcriptome sequencing and epigenetic characterization, i.e. the models would have the same data as are available for CMDC generated models. For the models for which clinical data is available, it would be collected as well (collected under a different mechanism). This would increase the number of models available for large scale screening studies, increase the number of tumor subtypes available through the developed distribution pipeline and for a modest investment enlarge the number of models that NCI provides to the community. It is estimated that up to 200 NGCMs would be added through this pipeline.